P3 Health Partners Inc. (PIII)
| Market Cap | 94.01M +53.1% |
| Revenue (ttm) | 1.47B -0.9% |
| Net Income | -126.25M |
| EPS | -38.54 |
| Shares Out | 7.24M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 280,739 |
| Open | 13.36 |
| Previous Close | 13.20 |
| Day's Range | 12.21 - 14.40 |
| 52-Week Range | 1.52 - 14.89 |
| Beta | 0.47 |
| Analysts | Buy |
| Price Target | 14.00 (+7.78%) |
| Earnings Date | May 14, 2026 |
About PIII
P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. The company was founded in 2020 and is based in Henderson, Nevada.
Financial Performance
In 2025, P3 Health Partners's revenue was $1.46 billion, a decrease of -2.76% compared to the previous year's $1.50 billion. Losses were -$147.95 million, 8.91% more than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for PIII stock is "Buy." The 12-month stock price target is $14.0, which is an increase of 7.78% from the latest price.
News
P3 Health Partners price target raised to $14 from $3 at TD Cowen
TD Cowen raised the firm’s price target on P3 Health Partners (PIII) to $14 from $3 and keeps a Hold rating on the shares. The firm said they reported 1Q26…
P3 Health Partners Inc trading resumes
09:50 EDT P3 Health Partners (PIII) Inc trading resumes
P3 Health Partners Inc trading halted, volatility trading pause
09:40 EDT P3 Health Partners (PIII) Inc trading halted, volatility trading pause
P3 Health Partners price target raised to $14 from $4 at Lake Street
Lake Street raised the firm’s price target on P3 Health Partners (PIII) to $14 from $4 and keeps a Buy rating on the shares. The transitional year of 2025 is…
P3 Health Partners reports Q1 EPS 32c vs ($6.28) last year
Reports Q1 revenue $386M vs $373M last year. “Q1 represents a meaningful turning point for the business. The $26 million of adjusted EBITDA we delivered this quarter reflects the cumulative…
P3 Health Partners sees FY26 revenue $1.5B-$1.65B
Sees FY26 adjusted EBITDA $20M-$60M
P3 Health Partners Earnings Call Transcript: Q1 2026
Q1 delivered $26M adjusted EBITDA, exceeding expectations, with revenue up year-over-year despite lower membership. Structural improvements, disciplined execution, and favorable macro trends led to a raised 2026 outlook of $20–$60M adjusted EBITDA.
P3 Health Partners Earnings release: Q1 2026
P3 Health Partners released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
P3 Health Partners Quarterly report: Q1 2026
P3 Health Partners has published its Q1 2026 quarterly earnings report on May 14, 2026.
P3 Health Partners Announces First Quarter 2026 Results
HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its financi...
P3 Health Partners Slides: Investor presentation
P3 Health Partners has posted slides in relation to its latest quarterly earnings report, which was published on May 14, 2026.
P3 Health Partners Proxy statement: Proxy filing
P3 Health Partners filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
P3 Health Partners Proxy statement: Proxy filing
P3 Health Partners filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
P3 Health Partners enters debt exchange pact with largest stock and debt holder
In a regulatory filing last night, P3 Health Partners (PIII) reported that the company and P3 Health Group, a wholly owned subsidiary of the company, entered into a Debt Exchange…
P3 Health Partners Proxy statement: Proxy filing
P3 Health Partners filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
P3 Health Partners Schedules First Quarter 2026 Earnings Release and Conference Call
HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that the Co...
P3 Health Partners price target lowered to $3 from $6 at TD Cowen
TD Cowen analyst Gary Taylor lowered the firm’s price target on P3 Health Partners (PIII) to $3 from $6 and keeps a Hold rating on the shares. The firm updated…
P3 Health Partners price target lowered to $4 from $12.50 at Lake Street
Lake Street analyst Ben Haynor lowered the firm’s price target on P3 Health Partners (PIII) to $4 from $12.50 and keeps a Buy rating on the shares. The transitional year…
P3 Health Partners Slides: Investor presentation
P3 Health Partners has posted slides in relation to its latest quarterly earnings report, which was published on March 27, 2026.
P3 Health Partners Earnings Call Transcript: Q4 2025
Guidance for 2026 targets a $10 million Adjusted EBITDA midpoint, a $170 million improvement year-over-year, driven by contract, operational, and cost structure enhancements. Expansion into a new Medicare Advantage market adds 29,000 members and a multi-year glide path to risk.
P3 Health Partners Annual report: Q4 2025
P3 Health Partners has published its Q4 2025 annual report on March 26, 2026.
P3 Health Partners Earnings release: Q4 2025
P3 Health Partners released its Q4 2025 earnings on March 26, 2026, summarizing the period's financial results.
P3 Health Partners reports Q4 revenue $384.8M, two estimates $357.7M
Q4 net loss was $165.7M vs. loss of $129.1M last year. “2025 was a year of meaningful progress in repositioning the business. We strengthened our contract economics, improved provider alignment,…
P3 Health Partners sees FY26 adjusted EBITDA ($20M)-$40M vs. ($161.3M) in FY25
16:08 EDT P3 Health Partners (PIII) sees FY26 adjusted EBITDA ($20M)-$40M vs. ($161.3M) in FY25
P3 Health Partners Announces Fourth Quarter and Full Year 2025 Results
HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its financi...